Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
26.43
+0.03 (+0.11%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,461,722
Open
26.38
Bid (Size)
26.31 (1)
Ask (Size)
26.48 (2)
Prev. Close
26.40
Today's Range
26.33 - 26.63
52wk Range
25.10 - 31.66
Shares Outstanding
388,132,400
Dividend Yield
3.18%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
November 14, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade
November 14, 2024
Via
The Motley Fool
Performance
YTD
-6.51%
-6.51%
1 Month
-3.12%
-3.12%
3 Month
-6.97%
-6.97%
6 Month
-0.79%
-0.79%
1 Year
-2.33%
-2.33%
More News
Read More
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
November 07, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
November 06, 2024
Via
Benzinga
Insights Ahead: Royalty Pharma's Quarterly Earnings
November 05, 2024
Via
Benzinga
Peering Into Royalty Pharma's Recent Short Interest
October 08, 2024
Via
Benzinga
Royalty Pharma Reports Third Quarter 2024 Results
November 06, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
November 04, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income
October 20, 2024
Via
The Motley Fool
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
October 16, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2024 Dividend
October 11, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
2 No-Brainer Dividend Stocks to Buy With $100 in October
October 01, 2024
Via
The Motley Fool
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
September 28, 2024
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 18, 2024
Via
Benzinga
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
September 16, 2024
Via
The Motley Fool
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
September 08, 2024
Via
The Motley Fool
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
September 04, 2024
Via
Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 03, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
August 28, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
August 16, 2024
Via
Benzinga
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Royalty Pharma Reports Second Quarter 2024 Results
August 08, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
July 24, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Third Quarter 2024 Dividend
July 17, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.